Market Intelligence, Clinical Progress, and High-Purity Reagents for Targeted Oncology & Resistance Management.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for RET G691S drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (RET G691S Mutant) | RET G691S Mutant Recombinant Protein (Kinase Domain). High purity (>95%), Endotoxin <1EU/µg. Sequence Verified by Mass Spectrometry. ATP-binding site intact. | View RET G691S Products |
| Antigen (Wild-Type Control) | RET WT Kinase Domain Protein. For selectivity discrimination assays (Mutant vs WT window determination). | View RET Products |
| Gene Delivery | RET G691S Lentivirus Premade Particles. Full-length ORF containing the G691S variant. High titer (>10^8 TU/mL) for stable cell line generation. | View RET G691S Products |
| Benchmark Ab | Anti-RET (Sequence of Selpercatinib / Pralsetinib Control Frameworks). Recombinant positive control for assay benchmarking and kinase binding assays. | View RET Products |
| Validator | RET siRNA Set. For knockdown verification and specificity checks in RET-driven cellular models. | View RET Products |
| Related Target A (Resistance) | RET V804M. Gatekeeper resistance mutation; critical counter-screening target for next-generation TKIs. | View RET V804M Products |
| Related Target B (Resistance) | RET G810R. Solvent-front resistance mutation emerging after first-line selective RET inhibitor therapy. | View RET G810R Products |
| Related Target C (Safety) | VEGFR2 (KDR). Primary off-target liability causing vascular toxicity; mandatory selectivity counter-screen. | View VEGFR2 Products |
| Fusion Context | KIF5B-RET. Common oncogenic fusion partner for RET-driven NSCLC. | View KIF5B-RET Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Mutant vs Wild-Type Selectivity Profiling | Matched Protein Pair: RET G691S vs RET WT (Human, HEK293 expressed, >95% purity, Endotoxin <1 EU/µg). Sequence-verified kinase domain proteins. |
| Cellular Resistance Modeling (Juxtamembrane Variants) | Lentivirus premade particles with EF1α promoter ensuring high, stable expression in Ba/F3 or HEK293 cells. Preserves native membrane topology. |
| Off-Target Kinase Safety (VEGFR2 Counter-Screen) | Comprehensive kinase homolog panel (VEGFR1/2/3, EGFR) strictly verified by mass spectrometry and SDS-PAGE. |
| Standardized Assay Controls | High-purity wild-type RET and benchmark reference kinase control reagents included for robust experimental baselines. |
| False Positives in Cellular Proliferation Assays | Validated RET-specific siRNA included for rigorous biological specificity and knockdown verification. |
| Fusion Protein Context Assays | Native full-length ORF available for KIF5B-RET fusion constructs for comprehensive resistance profiling. |
Live RET G691S R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for RET-targeted therapeutics is intensifying, with major pharmaceutical players shifting focus from non-selective multi-kinase inhibitors (e.g., Vandetanib, Cabozantinib) to highly selective, brain-penetrant next-generation tyrosine kinase inhibitors (TKIs). While first-generation selective agents like Selpercatinib and Pralsetinib have revolutionized the clinical management of RET-fusion non-small cell lung cancer (NSCLC) and medullary thyroid carcinoma (MTC), the emergence of secondary resistance mutations and polymorphic modifiers necessitates continuous pipeline evolution.
The juxtamembrane/kinase domain variant RET G691S has garnered increasing clinical attention due to its potential to alter receptor structural dynamics, influence baseline auto-phosphorylation kinetics, and modulate patient responsiveness or resistance profiles when co-occurring with oncogenic drivers. Consequently, the next wave of drug discovery is heavily focused on macrocyclic compounds, next-generation brain-penetrant TKIs (such as NVL-655) designed to overcome solvent-front (G810R/S/C), gatekeeper (V804M/L), and structural modifier variants like G691S, as well as proteolysis-targeting chimeras (PROTACs) and rational combination therapies targeting parallel survival pathways, while strictly sparing VEGFR2 to eliminate off-target vascular toxicities.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Selective Small Molecule TKI | Eli Lilly (Selpercatinib), Roche / Blueprint (Pralsetinib) | NSCLC (RET-fusion positive), Medullary Thyroid Carcinoma | High-Throughput Kinase Assay (Need high-purity recombinant RET G691S and WT kinase domain proteins) |
| Next-Gen Brain-Penetrant TKI | Nuvalent (NVL-655), Turning Point / BMS (Repotrectinib) | TKI-Refractory NSCLC, Brain Metastases, Resistance Mutations | Selectivity & Counter-Screening (Need mutant panels: G691S, V804M, G810R vs. VEGFR2 counter-screens) |
| Allosteric Inhibitor / PROTAC Degrader | Preclinical Biotech Pipelines (e.g., Cullinan Oncology, C4 Therapeutics) | Refractory Advanced Solid Tumors | Cellular Degradation & Mechanistic Validation (Need RET G691S Lentivirus for stable Ba/F3 and HEK293 reporter models) |
| Combination Therapy | Eli Lilly, Roche/Genentech | Medullary Thyroid Cancer, TKI-Resistant NSCLC | Pathway Cross-talk Analysis (Need KIF5B-RET fusion constructs and cellular models) |